Supplementary file
Published: 29 April 2024| Version 1 | DOI: 10.17632/hmyd3m5yfw.1
Contributors:
Kexiang Yan, Ling Han, Zhenghua Zhang, Fuqiu Li, Xiaodong Bi, Rixing Chen, Yuye Li, Litao Zhang, Xiaohua Wang, Linfeng Li, Jianyun Lu, Aie Xu, Sen Yang, Yan Lu, Jiangfang Sun, Zhiming Li, Xiaohong Zhu, Meiying Jiang, Siping Zhang, Wenqing Wang, Yanling Li, Zudong Meng, Hongyi Li, Kuanhou Mu, Xiuping Han, Shanshan Li, Ai-Jun Chen, Xin Li, Donghua Liu, Chunlei Zhang, Chao Ji, wang yu, Hao Cheng, Xiaojing Cui, Xiaoyan Yao, Xiaoyan Bai, Guangchao Dong, Jinhua XuDescription
Supplementary file to: Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial
Files
Steps to reproduce
Not applicable
Categories
Clinical Trial
Funding
Jiangsu Hengrui Pharmaceuticals